Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Karissa Hoeme

Physician Assistant Parker, CO Physician Assistant

NPI 1144651696 CMS profile 10520356

11960 Lioness Way Ste 130, Parker, CO 80134

Open in the dashboard

General payments

$11,268

465 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karissa Hoeme of Parker, CO is reported in the CMS Open Payments database as having received $11,268 across 465 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,823 71
2024 General $2,272 90
2023 General $2,962 116
2022 General $2,287 123
2021 General $1,925 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karissa Hoeme
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Karissa Hoeme were reported at $1,823. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Karissa Hoeme Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,925 $132 $37–$438 $132
2022 $2,287 $155 $48–$522 $149
2023 $2,962 $167 $52–$557 $160
2024 $2,272 $178 $55–$600 $164
2025 $1,823 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $2,351 41 payments
  2. AbbVie, Inc. $1,860 108 payments
  3. Collegium Pharmaceutical, Inc. $908 63 payments
  4. Scilex Pharmaceuticals Inc. $661 42 payments
  5. Lundbeck LLC $659 28 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $377 19 payments
  7. Saluda Medical Americas, Inc. $359 7 payments
  8. Biohaven Pharmaceuticals, Inc. $346 9 payments
  9. Abbott Laboratories $325 5 payments
  10. Amgen Inc. $275 8 payments
  11. Other $3,146 135 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,268 465 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $1,134 80 payments
  2. UBRELVY $947 41 payments
  3. ZTLido $571 35 payments
  4. NURTEC ODT $567 20 payments
  5. General - Pain Management $518 9 payments
  6. XTAMPZA $414 28 payments
  7. VYEPTI $382 19 payments
  8. Evoke $359 7 payments
  9. WaveWriter Alpha Prime 16 $355 9 payments
  10. Qutenza $338 20 payments
  11. Other $6,178 247 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

3,645

Median for Physician Assistant: 241

Drug cost

$316,822

Median for Physician Assistant: $4,110

Branded share of claims

35.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucynta Er Tapentadol Hcl Brand 36 $60,998
Xtampza Er Oxycodone Myristate Brand 70 $43,348
Buprenorphine Generic 84 $23,470
Belbuca Buprenorphine Hcl Brand 26 $23,011
Oxycontin Oxycodone Hcl Brand 34 $18,855
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 361 $15,641
Fentanyl Generic 69 $14,890
Aimovig Autoinjector Erenumab-Aooe Brand 17 $12,855
Oxycodone Hcl Generic 602 $12,125
Movantik Naloxegol Oxalate Brand 16 $12,012

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$18,897

Of which drugs: $2,948

Medicare patients

86

Average age 68

Services billed

1,500

61 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Depression 50%
Chronic kidney disease 28%
Osteoporosis 26%
Diabetes 21%
COPD 20%
Ischemic heart disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 144 $112

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $171
$171 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $166
$166 14 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $126
$126 70 —
VYEPTI
  • Lundbeck LLC $120
$120 — —
Qutenza
  • Averitas Pharma Inc. $102
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

465 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record